Yellow Fever Vaccine for Yellow Fever
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how the yellow fever vaccine affects the immune system, with a focus on the impact of infections on immune responses. Researchers will study individuals from Uganda and Minnesota, collecting samples before and after vaccination to understand the relationship between infections and vaccine response. Participants must not have had yellow fever or received its vaccine and must not be immunosuppressed. As a Phase 1 and Phase 2 trial, this research aims to understand the vaccine's function and measure its effectiveness in a smaller group, offering participants a chance to contribute to groundbreaking vaccine research.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but if you are on immunosuppressive drugs, you may not be eligible to participate.
Is there any evidence suggesting that the Yellow Fever Vaccine is likely to be safe for humans?
Research has shown that the yellow fever vaccine is generally safe, but some risks exist. Most people experience mild side effects such as headaches, muscle aches, or a slight fever. However, in rare instances, the vaccine can cause serious health problems, including severe allergic reactions that might affect organs like the liver or kidneys.
Although uncommon, these serious reactions have occurred. Out of 23 reported serious cases, 14 were fatal. It is important to weigh these risks against the benefits, especially in areas where yellow fever poses a threat. Discuss any concerns or health conditions with a healthcare provider to understand how they might affect your reaction to the vaccine.12345Why are researchers excited about this trial?
Researchers are excited about the Yellow Fever Vaccine because it offers a promising solution to protect against yellow fever, a potentially deadly viral infection. Unlike other treatments that primarily focus on managing symptoms once infected, this vaccine aims to prevent the disease altogether by stimulating the immune system to build a defense before exposure. Vaccination remains the most effective strategy for controlling yellow fever outbreaks, and this new vaccine is being studied to ensure it provides robust and long-lasting immunity with potentially fewer side effects.
What evidence suggests that the Yellow Fever Vaccine might be an effective treatment for Yellow Fever?
Research has shown that the yellow fever vaccine is highly effective. A single shot can provide lifelong protection, with 80–100% of individuals becoming immune within 10 days. Over 99% of those vaccinated gain protection shortly after receiving the shot. This indicates that the vaccine effectively guards against yellow fever for nearly everyone who receives it. Instances where the vaccine fails are rare, underscoring its strong success rate.678910
Who Is on the Research Team?
Timothy Schacker, MD
Principal Investigator
University of Minnesota
Are You a Good Fit for This Trial?
This trial is for healthy adults without immune system issues who haven't had the yellow fever vaccine before. Women of childbearing age must avoid pregnancy for a month after vaccination. People with bleeding disorders, severe allergies to vaccine components, or those on immunosuppressive therapy cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-Vaccination Assessment
Participants undergo lymph node and adipose tissue biopsy and leukapheresis before vaccination
Vaccination
Participants receive the yellow fever vaccine
Post-Vaccination Assessment
Participants undergo a second lymph node biopsy and leukapheresis 3 weeks after vaccination
Follow-up
Participants are monitored for safety and effectiveness, with regular collection of PBMC, plasma, urine, and stool over 18 months
What Are the Treatments Tested in This Trial?
Interventions
- Yellow Fever Vaccine
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Minnesota
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator